The Impact of Angelina Jolie's Story on Genetic Referrals

In an interview with Targeted Oncology, Yael Schenker, MD, MAS, FAAHPM, discussed the importance of palliative care and advanced care planning for patients with advanced cancers.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.